Skip to main content
Premium Trial:

Request an Annual Quote

Precision Therapeutics Raises $20M to Develop Chemotherapy Response Test

NEW YORK, Feb. 21 (GenomeWeb News) - Precision Therapeutics said today that it closed a $20 million series B funding round.

 

The funding will be used to commercialize the Precision's ChemoFx assay, a cell-based test that "quantifies an individual patient's likely tumor response to single or multiple chemotherapeutic agents," the company said in a statement.

 

Lead investor in the round was Quaker BioVentures of Philadelphia. Existing investors included Adams Capital Management, Birchmere Ventures, Techno Venture Management and Draper Triangle Ventures.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.